Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
Anteris Technologies Global Corp. (AVR) is soliciting stockholder votes on 23 proposals at its annual meeting on December 2, 2026, including election of David St Denis and Stephen Denaro as Class II directors and ratification of KPMG as independent registered public accounting firm for fiscal 2026. Proposals 3–5 seek approval of 629,921 RSUs for Wayne Paterson, 314,960 RSUs for David St Denis, and 39,123 RSUs for Susan Knight.
Other proposals cover 2026 option-right and performance-based RSU awards, amendments to previously granted RSUs, and common stock or CDI issuances instead of director cash retainers, including up to $540,000 in aggregate grant date value of Common Stock for John Seaberg. The Board recommends voting FOR all 23 proposals. Stockholders of record as of October 29, 2026 may vote; CDI holders may attend as guests and must direct CHESS Depositary Nominees Pty Ltd to vote underlying shares before the meeting.
Anteris Technologies Global Corp. (AVR) disclosed that L1 Long Short Fund Limited, L1 Capital Long Short Fund and L1 Capital Long Short (Master) Fund, all controlled and managed by ten-percent owner L1 Capital Pty Ltd, purchased 272,695 common shares on October 6, 2026, at 7.18 per share across transactions priced from 7.10 to 7.29. The reported resulting position was 6,358,271 common shares; no Rule 10b5-1 plan is reported.
Other indirect holdings attributed to L1 Long Short Fund Limited, L1 Capital Long Short Fund, L1 Capital Long Short (Master) Fund, L1 Capital Global Long Short (Master) Fund, L1 Capital Global Long Short Fund, L1 Capital Global Long Short (AUD Offshore) Fund and L1 Global Long Short Fund Limited, all controlled and managed by L1 Capital Pty Ltd, included 5,359,470 CHESS Depository Interests and 1,333,334 CHESS Depository Interest Warrants. The warrants have an AUD 11.50 exercise price, are exercisable within 60 days subject to the exercise price and expiry date, and expire October 30, 2030.
Anteris Technologies Global Corp. (AVR) reports purchases by three funds controlled and managed by L1 Capital Pty Ltd, identified as a 10% owner: 236,354 common shares on October 2, 2026, at per-share prices ranging from $7.74 to $7.87, and 648,455 shares on October 5, 2026, at prices ranging from $7.38 to $7.52. The report also lists indirect positions as of October 2, 2026, of 5,359,470 CHESS Depository Interests, exchangeable for common shares within 60 days, and 1,333,334 CHESS Depository Interest Warrants with an AUD 11.50 exercise price and an October 30, 2030 expiration date.
Anteris Technologies Global Corp. (AVR) disclosed indirect purchases of its common stock by funds controlled and managed by L1 Capital Pty Ltd, identified as a 10% owner: 74,286 shares on September 30, 2026, at prices ranging from $7.72 to $7.75 per share, and 322,940 shares on October 1, 2026, at prices ranging from $7.59 to $7.76 per share. No Rule 10b5-1 plan is reported. The listed indirect holdings also include CHESS Depository Interests, which represent one underlying common share and are exchangeable within 60 days, and CHESS Depository Interest Warrants, which represent one CDI each and are exercisable within 60 days subject to the exercise price and expiry date.
Anteris Technologies Global Corp. (AVR) has a prospectus covering the resale by selling stockholders of up to 9,103,796 shares of common stock. Its wholly owned subsidiary, Anteris Aus Operations Pty Ltd, amended its Supply & Quality Agreement with Harvey Industries Group Pty Ltd, extending the term to expire on the earlier of December 31, 2026, or execution of a separate replacement agreement. All other material terms remain unchanged.
Anteris Technologies Global Corp. (AVR), through its wholly owned subsidiary Anteris Aus Operations Pty Ltd, amended its Supply & Quality Agreement with Harvey Industries Group Pty Ltd on September 22, 2026. The agreement term now expires on the earlier of December 31, 2026, or the execution of a separate supply and quality agreement intended to replace it. All other material terms remain unchanged and in full force and effect.
Anteris Technologies Global Corp. (AVR) has filed a prospectus supplement linked to its Form S-1 covering up to 9,103,796 shares of common stock that may be resold by selling stockholders. The supplement incorporates a current report describing new equity incentives for key executives and an employee.
The company approved contingent grants of nonqualified stock options and performance-based restricted stock units for Wayne Paterson and David St Denis, all subject to stockholder approval, with multi‑year vesting, change‑in‑control protections and stock‑price performance hurdles. A separate nonqualified option grant with time-based vesting was approved for Matthew McDonnell.
Anteris Technologies Global Corp. (AVR) approved significant equity awards for senior executives and a key employee, primarily in the form of nonqualified stock options and performance-based restricted stock units, with most grants contingent on stockholder approval.
Wayne Paterson was approved for 1,200,000 stock options and 800,000 PSUs, and David St Denis for 414,000 stock options and 485,000 PSUs, all granted on September 13, 2026 with 10-year terms for the options and multi-year vesting. The PSU awards vest over a five-year period based on achieving stock price hurdles of $21.50, $41.00, and $61.50, with accelerated vesting on death, disability, or certain change-in-control events. Separately, Matthew McDonnell received a nonqualified option grant over CHESS Depositary Interests with a target value of $500,000, vesting over three years and subject to similar change-in-control and forfeiture conditions.
Anteris Technologies Global Corp. (AVR) reported that its Chief Financial Officer, Moen Brent, received a grant of 90,274 employee stock options on September 11, 2026. The options have an exercise price of $8.35 per share, expire on September 11, 2036, and vest in approximately equal installments on September 11, 2027, 2028, and 2029, subject to continued service.